Late-Breaking Abstracts

Late-Breaking Abstracts - Clinical Only (LBA)

Late-breaking Abstracts no longer have an application requirement.
If a Late-breaking Abstract is not accepted, it will not be presented at the meeting.

Abstract Dates Abstract FAQsAbstract Reference Guide

Late-Breaking Abstract - Clinical Only (LBA) Information and Eligibility

Late-breaking Abstract (LBA) submission is solely for abstracts with late-breaking data from interventional clinical trials in humans and not for abstracts submitted “late.” The LBA deadline is not intended to be an extension of the general submission deadline. LBAs highlight novel and practice-changing in-human clinical studies and only apply to data that would have not otherwise have been presented as an abstract at the 39th Annual Meeting.

  Authors of LBAs do not need to submit an application or a place-holder abstract. LBAs should be submitted during the LBA submission period, from July 15–Sept. 12 at 5 p.m. PDT.

If a Late-breaking Abstract is not accepted, it will not be published or presented at the meeting. There is no longer an option for it to be considered as a Regular/YIA Abstract.

NEW IN 2024: Late-Breaking Abstracts - Clinical Only (LBAs)

Clinical Abstracts: LBAs must address interventional clinical trials in humans. LBAs addressing basic science or translational data with no in-human studies will not be accepted. LBAs may contain data from preclinical studies, but they must also include clinical data from in-human trials. Authors will need to justify why the abstract is considered late-breaking. Clinical trial LBAs should be submitted during the LBA submission period, from July 15–Sept. 12 at 5 p.m. PDT.

 NEW IN 2024: Late-Breaking Abstracts - Clinical Only (LBAs)

Guidelines for Basic or Translational Abstracts: Because LBAs will be limited to clinical studies, authors submitting an abstract of a basic science or translational study must submit their abstract by the Regular/YIA Abstract deadline of June 27 at 5 p.m. PDT. If some results from the study are not available before the abstract submission deadline, authors are encouraged to submit an abstract by the deadline and include the new data in their abstract presentation.

Examples of acceptable LBAs include the following (in each case, results were not available or significant by the regular abstract submission deadline):

  • Results of a practice-changing prospective Phase III clinical trial
  • Phase II study showing anti-tumor activity in a novel context
  • An early in-human clinical trial with novel proof-of-principle data

LBAs are considered for a limited allocation of oral and poster presentation slots on either Friday, Nov. 8 or Saturday, Nov. 9. The data in the abstract must not be published prior to SITC 2024.

LBA Oral Presentation Opportunities

LBAs are considered for, but not limited to, oral abstract presentations during the LBA Sessions from 11:45 a.m.–12:15 p.m. on Friday, Nov. 8, 2024 and 11:45 a.m.–12:15 p.m. on Saturday, Nov. 9, 2024.

Late-Breaking Abstracts - Clinical Only (LBA) Additional Fields

Late-Breaking Abstracts – Clinical Only (LBA) submission is solely for abstracts with late-breaking data from interventional clinical trials in humans and not for abstracts submitted “late”. LBAs will need to include the following information in their abstract:

  • Closure date of the study
  • Primary clinical endpoint for analysis
  • Type of analysis
  • Provide an explanation why the abstract should be considered for late-breaking submission

This information will not be included in the JITC Abstract Supplement, but will be provided to reviewers during the review process.

Important Late-Breaking Abstract - Clinical Only (LBA) Dates

July 15, 2024
LBA Submission Site Opens

Sept. 12, 2024
LBA Submission Site Closes at 5 p.m. PDT

Sept. 25, 2025
LBA Notifications Sent

Sept. 30, 2024
LBA Presentation Acceptance Confirmation Due/Deadline for LBA Withdrawals (Withdrawals must be made by emailing education@sitcancer.org to Indicate a Withdrawal)

Oct. 30, 2024
LBA Title and Author Information Released at 9 a.m. EDT

Nov. 5, 2024
Embargo Lifted and Full Regular and LBA Made Public at 8 a.m. CST/9 a.m. EST. All accepted abstract are available in the JITC Supplement

Nov. 6–10, 2024
39th Annual Meeting & Pre-Conference Programs

Feb. 2025
Final Supplement Published in JITC

941.jpg
941.jpg